NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have earned an average rating of “Moderate Buy” from the five analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $14.00.

Several analysts have commented on the company. D. Boral Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of NeuroSense Therapeutics in a research note on Monday, December 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research note on Monday. Wall Street Zen downgraded NeuroSense Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Zacks Research upgraded shares of NeuroSense Therapeutics to a “hold” rating in a research report on Wednesday, October 15th. Finally, Noble Financial upgraded shares of NeuroSense Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 14th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in NRSN. Two Sigma Investments LP purchased a new stake in NeuroSense Therapeutics in the 3rd quarter valued at approximately $26,000. Squarepoint Ops LLC raised its stake in shares of NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after buying an additional 45,450 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of NeuroSense Therapeutics in the 2nd quarter valued at approximately $54,000. 1.04% of the stock is owned by hedge funds and other institutional investors.

NeuroSense Therapeutics Stock Down 6.6%

Shares of NASDAQ:NRSN opened at $0.71 on Wednesday. NeuroSense Therapeutics has a one year low of $0.70 and a one year high of $2.60. The company has a 50-day simple moving average of $1.01 and a 200-day simple moving average of $1.34.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.